Tylenol maker Kenvue’s stock rose in European trading on Tuesday, rebounding from a record low after US President Donald Trump linked its pain medication to autism risk during pregnancy. Analysts expect the recovery due to a lack of new evidence, but doctors reject the claim and Kenvue warned that such suggestions could harm maternal health. The FDA plans to update labels to reflect possible links between acetaminophen use during pregnancy and neurological conditions like autism and ADHD.
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/tylenol-maker-kenvue-shares-bounce-trump-claims-face-pushback-2025-09-23